Highlights {#Sec100}
==========

Hypercoagulable status is common in critically ill COVID-19 patients.The low activities of natural anticoagulants, elevated factor VIII level and the presence of antiphospholipid antibodies may contribute to the coagulopathy of COVID-19.

Introduction {#Sec1}
============

Coronaviruses are important pathogens in humans that can cause diseases ranging from the common cold to more severe and even fatal respiratory infections. Since the outbreak of the novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019 in Wuhan, China, more than 2,000,000 cases have been diagnosed globally to date and the number is still growing rapidly. Patients infected with COVID-19 develop from mild, self-limiting respiratory tract illness to severe progressive pneumonia associated with multi-organ failure \[[@CR1]--[@CR4]\].

Recently, coagulopathy was reported widely present in severe SARS-CoV-2 infected patients and disseminated intravascular coagulation (DIC) developed in the majority of non-survivors \[[@CR5]\]. The increase of D-dimer and clinical signs of organ damage indicating a significant hypercoagulable status were implicated in the formation of wide-spread microthrombi and multi-organ ischemia \[[@CR6], [@CR7]\]. Although the pathological effect of SARS-CoV2 infection on coagulation system is unknown, release of various proinflammatory cytokines, vascular endothelial cell injuries, and platelet activation may play a role in the process. Indeed, data on coagulation activation in viral infection like coronaviruses are sparse. More recently, we reported the emergence of antiphospholipid antibodies (aPL) in 3 critically ill COVID-19 patients with multiple cerebral infarction \[[@CR8]\]. The presence of these antibodies prompted us to further investigate the underlying mechanism of coagulopathy in COVID-19. Herein, we performed a cross-section study through analyzing coagulation profiles in 19 critically ill COVID-19 patients, to understand the coagulopathy of SASR-CoV2 infection, which may provide insights and guidance in clinical practice.

Methods {#Sec2}
=======

This single-center cross-sectional study included all critically ill patients who were admitted to the intensive care unit (ICU), Zhongfa campus of Tongji Hospital (Wuhan, China) between February 23 and March 3, 2020. The ICU was managed by the medical team from Peking Union Medical College Hospital (PUMCH). The patients were confirmed COVID-19 with oropharyngeal or nasopharyngeal swabs testing positive for SARS-CoV-2 by real-time reverse-transcription (PCR) using commercial kits (BGI BIOTECHNOLOGY (WUHAN) CO., LTD, Wuhan, China), according to the Chinese Recommendations for Diagnosis and Treatment of Novel Coronavirus (SARS-CoV-2) Infection (Pilot 4th version) \[[@CR9]\]. The treatments and outcomes (28-day mortality) were monitored up to March 30, 2020.

The study was approved by the Research Ethics Commission of Peking Union Medical College Hospital.

Data collection {#Sec3}
---------------

Epidemiological, demographic, clinical, laboratory results, treatment, and outcome data were extracted from electronic medical records. Routine blood tests include complete blood count, coagulation profiles, serum biochemical tests (including renal and liver function, creatine kinase, lactate dehydrogenase, and electrolytes).

The coagulation profiles, including prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (FIB), D-dimer, fibrinogen degradation products (FDP) and antithrombin (AT) were detected using a STA-R MAX coagulation analyzer and manufacturer-supplied reagents (or reagents supplied by the manufacturer) (Diagnostica Stago, Saint-Denis, France). Plasma activities of protein C, protein S, coagulation factor II, V, VII, VIII, IX, X, IX, XII were tested using STA-R MAX coagulation analyzer and manufacturer-supplied reagents (Diagnostica Stago, Saint-Denis, France) as well.

Serum aPLs determination {#Sec4}
------------------------

Serum anti-cardiolipin (aCL) antibodies (IgG, IgM and IgA) and anti-β2-glycoprotein 1 (aβ2GP1) antibodies (IgG, IgM, and IgA) were determined by the chemiluminescence assay (CIA) (QUANTA Flash® assays, INOVA Diagnostic, Inc.) according to the manufacturer's instructions. The cutoff values for positivity were set \> 20 chemiluminescence units (CU) based on manufacturer's recommendations.

Lupus anticoagulant (LA) {#Sec5}
------------------------

The detection of LA in human citrated plasma was performed by the HemosIL dRVVT Screen and HemosIL dRVVT Confirm assays, as recommended by the International Society on Thrombosis and Haemostasis (ISTH).

The onset of the disease was defined when the symptoms were noticed. Disseminated intravascular coagulation (DIC) was defined according to International Society of Thrombosis & Hemostasis (ISTH) criteria of DIC \[[@CR10]\]. Sepsis-induced coagulopathy (SIC) was defined according to the Third International Consensus Definitions for Sepsis (sepsis-3) \[[@CR11]\]

Statistical analysis {#Sec6}
--------------------

Summary statistics were used to describe the study. Normal variables were summarized as means and standard deviations, and non-normal variables as medians and interquartile range (IQR). We used the χ^2^ test, Fisher's exact test or Mann--Whitney test to compare differences where appropriate. All statistical procedures were performed using SPSS 25.0 software (SPSS Inc., Chicago, IL, USA).

Results {#Sec7}
=======

Clinical data {#Sec8}
-------------

A total of 20 patients were admitted to the ICU ward between February 23 and March 3, 2020 with confirmed COVID-19 infection. Out of 20, 19 patients with integrated medical records were included in this study. One patient was excluded due to a lack of coagulation test results. All patients fulfilled the critically ill subtype according to the Diagnosis and Treatment Plan of COVID-19 suggested by National Health Commission of China \[[@CR12]\].

The median age of the patients was 65.0 years (36--80). 14 patients (73.6%) were older than 60 years. Sex distribution (F:M = 9:10) was similar. Fourteen patients had underlying comorbidities, including hypertension, diabetes mellitus, stroke, chronic obstructive pulmonary disease, and malignancy. The median duration from onset to admission to ICU was 21 days (IQR 13--24.75). The treatments before ICU admission included: antiviral drugs (17/19), glucocorticoids (15/19), intravenous immunoglobulin (19/19), and antibiotics (18/19). All the patients received respiratory support after admission to ICU, 17(89.4%) patients required endotracheal intubation and mechanical ventilation. The other supportive treatments included fluid management, nutritional support, antibiotics, continuous renal replacement therapy (2 patients) and extracorporeal membrane oxygenation (ECMO, for 1 patient). Due to the significant hypercoagulable status, 17 patients received low molecular weight heparin (LMWH) 4000--6000 IU, subcutaneous injection, twice per day. The 28-day mortality in ICU was 68.42%, and the median duration in ICU of non-survivors was 14 (IQR 9--14) days (Table [1](#Tab1){ref-type="table"}).Table 1Clinical characters of critically ill patients with COVID-19Terminal stage (N = 5)Non-terminal (N = 14)Total (N = 19)Age (median)71 (63--72)65 (59--68)65 (60--70)Male (n, %)3 (60%)7 (50%)10 (52.6%)Comorbidity (n, %)4 (80%)8 (57.2%)12 (63.2%)The interval from Onset to sampling (days, IQR)29 (23--30)30 (20--33.5)30 (29--32)Survival time (days, IQR)30 (24--31)50 (39.25--64.75)40 (32--62)SIC scores at sampling (IQR)5 (4--6)2.5 (2--4)3 (2--5)SOFA scores at sampling (IQR)13 (11.5--15.5)7.5 (5.5--10.25)9 (6--13)Overt-DIC scores at sampling (IQR)4 (3--4)2 (2--3)3 (2--3.5)Thrombotic events01212Arterial thrombosis044Venous thrombosis011Micro-thrombi (acro-ischemia)077Bleeding events1^a^01^a^*DIC* disseminated intravascular coagulation, *SOFA* sequential organ failure assessment, *SIC* sepsis-induced coagulopathy^a^only 1 gastrointestinal bleeding event occurred after anticoagulation

Thrombosis events occurred in 9 patients (47.4%), including 7 acro-ischemia events, 4 cerebral infarction events and 1 jugular thrombosis event, as we reported previously \[[@CR6], [@CR8]\]. The median interval from disease onset to coagulation profile sampling was 30 days (IQR 29--32).

Coagulation profiles {#Sec9}
--------------------

All patients had significantly higher plasma D-dimer level (3.24 ± 1.98 μg/ml, normal range \< 0.5 μg/ml), and FVIII activities (329.95 ± 141.80%, normal range 60--150%); High fibrinogen level and prolonged PT were seen in 14 patients. 11 patients had prolonged APTT and 7 patients developed thrombocytopenia.

We divided the patients into two groups: 5 patients who died within 24 h after the coagulation profile sampling was defined as the terminal-stage group; the other 14 patients lived more than 3 days since the coagulation profile sampling belonged to non-terminal stage group. The clinical characteristics and coagulation results were compared between the terminal-stage and the non-terminal-stage group. The SOFA score and SIC score were significantly higher (p 0.010) in the terminal-stage group and were consistent with clinical outcome. We also observed the significantly prolonged PT (17.2 s vs.15.2 s, p 0.044) and lower platelet count (88.0 vs 214.0 × 10^9^/l, p 0.156) in the terminal-stage group. While the other routine coagulation parameters, including APTT, FIB, D-dimer and FDP, were similar between the two groups (Table [2](#Tab2){ref-type="table"}).Table 2Coagulation parameter profile in critically ill patients with COVID-19Terminal stage (N = 5)Non-termina (N = 14)Total (N = 19)P valuePLT (100--300 × 10^9^/l)88 (27.5--275)214 (160.25--251.5)202 (88--249)0.156PT (11.5--14.5 s)17.7 (16.35--19.6)15.2 (14.125--16.4)15.8 (14.5--17.7)0.044FIB (2.00--4.00 g/l)3.6 (2.85--5.965)4.8 (4.12--5.30)4.42 (3.6--5.22)0.298APTT (29.0--42.0 s)71.9 (40.35--75.4)46.75 (40.625--54.175)47.5 (40.9--56.1)0.257D-Dimer (\< 0.5 μg/ml FEU)3.61 (0.81--6.835)2.72 (1.995--4.105)2.72 (1.55--4.93)0.754FDP (\< 5.0 μg/ml)20.7 (13.7--20.7)11.75 (7.525--17.75)14.5 (7.975--20.65)0.533AT, (80--120%)59 (59--85)73 (67--89.5)72.5 (60.75--82.75)1.000PC (70--142%)66 (26--88.5)62 (56--106.5)63 (50--99)0.559PS (77--143%)81 (13--121)67.5 (39.25--83.5)70 (31--88)0.893FVIII (60--150%)316 (184.5--488.5)300 (216.5--414)307 (198--441)0.893FIX (60--150%)137 (76--169.5)143 (115.75--182.75)137 (119--176)0.500FXI (60--150%)54 (29.5--164.5)98.5 (32.5--97.25)92 (43--138)0.500FXII (50--150%)45 (33--85)56.5 (32.5--97.25)56 (43--87)0.687FII (70--120%)60 (26.5--69)64 (52.5--72.25)62 (45--72)0.391FV (70--120%)68 (50--106.5)160 (100--193.25)129 (73--190)0.005FVII (55--170%)58 (31--72.5)98.5 (77.25--107.25)93 (58--106)0.014FX (70--120%)51 (29--84.5)74 (47--89.25)73 (47--85)0.257All the parameters in this table were displayed by the form: median value, 25% to 75% IQR*aCL* anti-cardiolipin, *aβ2GP1* anti-β2-glycoprotein 1, *APTT* activated partial thromboplastin time, *AT* antithrombin, *FIB* fibrinogen, *FDP* fibrinogen degradation products, *LA* lupus anticoagulant, *PC* protein C, *PLT* platelet, *PT* prothrombin time, *PS* protein S

The levels of 3 natural anticoagulants were measured in this study. Protein C activities were below the normal range in both groups with the median activity of 63% (IQR 50--99). There was no significant difference between two groups (66% v.s. 62%, p 0.559). The finding in protein S and AT activities were similar (Table [2](#Tab2){ref-type="table"}).

In terms of coagulant factors, factor VIII activity was significantly above the normal range in both groups, but without any difference (316% v.s. 300%, p 0.893). Factor II, V, VII, IX, X, XI, XII activities for both patients groups maintained in the normal range. However, factor V and factor VII activities were much lower in the terminal-stage group than the non-terminal-stage group, which was consistent with the prolonged PT in that group. (see Table [2](#Tab2){ref-type="table"})

aPL profiles {#Sec10}
------------

10 out of 19 patients (52.6%) had positive serum aCL and/or aβ2GP1 autoantibodies, and 7 out of these 10 patients had multiple isotypes of aPLs (see Table [3](#Tab3){ref-type="table"}). All 4 patients who developed cerebral infarction during the hospitalization had aPLs with multiple isotypes. Interestingly, no thrombotic events occurred in 9 aPL negative patients. Moreover, the patients positive aPLs had a lower 28-day mortality compared to those with negative aPL (40.0% vs 88.9%, odd ratio 0.074, 95% CI 0.139--0.871, p 0.057). Only 1 patient in terminal-stage group had positive LA accompanied with high level of multiple aPLs (IgA aCL \> 352.0 CU, IgA aβ2GP1 396.7 CU, IgG aCL 20.2 CU, IgG aβ2GP1 45.5 CU).Table 3Antiphospholipid antibodies isotypes of critically ill patients with COVID-19aCLaβ2GP1LAIgAIgGIgMIgAIgGIgMPositive6217601*aCL* anti-cardiolipin, *aβ2GP1* anti-β2-glycoprotein 1, *LA* lupus anticoagulant

Discussion {#Sec11}
==========

In the last two decades, two beta coronavirus epidemics have been identified as the cause of acute severe respiratory disease: Severe Acute Respiratory Syndrome (SARS) in 2003 and Middle East Respiratory Syndrome (MERS) in 2012. The coagulopathy of SARS included isolated transient elevations of the activated PTT in the first 2 weeks of infection in 63% patients, but most patients had normal prothrombin times and no elevation of D-dimers. A total of 2.5% of SARS patients showed evidence of DIC \[[@CR13]\]. There has been no report about the incidence of coagulopathy in MERS. On the other hand, several studies have now demonstrated coagulopathy in SARS-Cov-2 infection since epidemic COVID-19 outbreak. However, none of the studies provided comprehensive coagulation evaluations \[[@CR5], [@CR14], [@CR15]\]. To the best of our knowledge, this is the first study to investigate natural anticoagulants, coagulation factors combined with aPLs in critical COVID-19 patients.

Our study revealed significant aberrant coagulation changes of critically ill COVID-19 patients admitted to ICU in several aspects: fibrinolytic degradation products (D-dimer & FDP) were significant above normal range in almost all patients; the levels of FIB and FVIII:C were above normal range in the majority of patients; the natural anticoagulant activities were mildly lower. Nearly half of patients developed thrombotic events after admission to ICU. These findings implied that sustained hypercoagulable status and activation of coagulation system are hallmarks of critically ill COVID-19, and provided a strong evidence to support anticoagulation therapy in these patients. These results are consistent with those from recent studies. Tang reported the elevated D-Dimer level in the inpatients with COVID-19 was related with higher mortality \[[@CR5]\]. A relative large scaled study from Netherlands showed the incidence of symptomatic thrombotic event was 31% in COVID-19 patients admitted to the ICU \[[@CR16]\]. Another retrospective study in France reported the overall rate of VTE in anticoagulated patients was as high as 69% after using a systematic VTE screening strategy \[[@CR17]\].

Different from prior studies, we not only tested the conventional coagulation parameters but also performed a comprehensive observation of coagulation system and natural anticoagulation system. Plasma levels of natural anticoagulants tend to be markedly reduced in patients with severe DIC \[[@CR18]\]. In patients with sepsis, multiple trauma and major surgery, a correlation between the reduction in AT and disease severity has been shown \[[@CR19]\]. AT and PC levels were related with hypercoagulable status and decreased levels develop earlier than overt DIC. Thus, AT and PC levels were considered diagnostic parameter for non-overt DIC in ISTH criteria \[[@CR10]\]. In this study, the median values of AT and PC activity were below lower limit of normal. These results suggest that SARS-Cov-2 infection can induce similar hemostatic change just like severe bacterial pneumonia or sepsis in association with the development of a large amount of micro-thrombi formation and the consumption of the natural anticoagulants.

High plasma levels of proinflammatory cytokines (interleukin-2, interleukin-6, tumor necrosis factor-α and so on) have been observed in SARS-Con-2 patients admitted to ICU, suggesting that a cytokine storm effect developing in these individuals with severe disease aggravating the coagulopathy \[[@CR20]\]. The significant elevated factor VIII activity and the high frequency of aPLs give us a clue for the explanation of sustained hypercoagulable state. This study showed that factor VIII activities were elevated in all patients. Factor VIII is a natural coagulant factor secreted by endothelial cells. Elevated plasma factor VIII coagulant activity (VIII:C) is widely accepted as an independent markers of increased thrombosis risk. In a population-based case control study, patients with factor VIII:C levels greater than 150% had an adjusted odds of 4.8 for thrombosis \[[@CR21], [@CR22]\]. The significantly elevated FVIII activity may be related with proinflammatory cytokines and contributes to the hypercoagulable status of COVID-19 patients.

Our preliminary data showed antiphospholid antibodies(aPLs) may be implicated in the exacerbation of hypercoagulable status. Most strikingly, all symptomatic thrombotic events occurred in aPL positive patients. IgA aCL, IgA aβ2GP1 and IgG aβ2GP1 were the most common antibodies in our study. This is different from immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections that mainly induces IgG aCL antibodies \[[@CR23]\]. IgA aβ2GPI has been described as an independent risk factor for acute myocardial infarction and acute cerebral ischemia \[[@CR24]\]. In this study, 4 patients who suffered cerebral infarction all had multiple aPLs including IgA aCL and aβ2GP1. Secondary antiphospholipid syndrome (APS) should be considered in COVID-19 patients with positive aPLs. Dynamic monitoring of aPLs levels may be useful to determine the persistence of aPLs and to confirm the diagnosis of APS.

In our study, longer PT and lower FVII and FV activities were observed in the terminal-stage group. Moreover, higher SIC and ISTH DIC scores were identified in those near-death patients. COVID-19 can lead to systemic injuries by attacking angiotensin-converting enzyme 2 (ACE2) expressed vascular endothelial cells. Endothelial cell damage and cytokines (especially interleukin 6) strongly induce the expression of tissue factor (TF) and subsequent activation of coagulation. The more obvious coagulation abnormalities may reflect that there were much severe and irreversible vascular endothelial cell injuries in the terminal-stage group. As a result, anticoagulation therapy may not be enough to stop the continuous activation of coagulation system in those patients and these patients may benefit from the addition of anti-cytokine storm treatment (such as tocilizumab).

This study had some limitations. First, this is a small-scale cross-section study. For practical reasons, we only repeated the conventional coagulation tests in our clinical practices with no dynamic surveillance of anticoagulants and coagulation factors. Second, only parts of coagulation and fibrinolysis parameters were tested. At last, due to the disease severity, head CT scan and deep vein thrombosis screen by ultrasound were performed in only symptomatic patients. If we had performed a systemic screening strategy, the incidence of thrombotic events would probably be even higher.

In conclusion, our current study demonstrated that the coagulopathy in critically ill COVID-19 patients was characterized by sustained hypercoagulable status and a high incidence of thrombotic events. The elevated FVIII:C activity combined with positive aPLs may be implicated in the mechanism of hypercoagulable status. Furthermore, the preliminary data showed a lower FV, FVII, and higher PT in terminal as compared to non-terminal COVID patients and may be valuable markers of advancing illness.
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